Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | thioredoxin reductase | 0.0194 | 1 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0098 | 0.2428 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0136 | 0.5444 | 0.5444 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0136 | 0.5444 | 0.5444 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0194 | 1 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0136 | 0.5444 | 0.5444 |
Plasmodium falciparum | glutathione reductase | 0.0194 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0194 | 1 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0194 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0098 | 0.2428 | 0.2428 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0067 | 0 | 0.5 |
Leishmania major | trypanothione reductase | 0.0194 | 1 | 1 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0098 | 0.2428 | 1 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0098 | 0.2428 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0194 | 1 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0194 | 1 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0067 | 0 | 0.5 |
Chlamydia trachomatis | glutamine binding protein | 0.0098 | 0.2428 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0067 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0067 | 0 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0194 | 1 | 1 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0098 | 0.2428 | 1 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0067 | 0 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0194 | 1 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0194 | 1 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0194 | 1 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0067 | 0 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0194 | 1 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0194 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
HACU improvement (functional) | = 10 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-5 M. | ChEMBL. | No reference |
HACU improvement (functional) | = 10 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-5 M. | ChEMBL. | No reference |
HACU improvement (functional) | = 11 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-6 M. | ChEMBL. | No reference |
HACU improvement (functional) | = 11 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-6 M. | ChEMBL. | No reference |
HACU improvement (functional) | = 15 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-7 M. | ChEMBL. | No reference |
HACU improvement (functional) | = 15 % | Effect on uptake amount of [3H]-choline in the hippocampal synaptosomes of AF64A-treated rats at a concentration of 10e-7 M. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.